ProfileGDS4814 / ILMN_1893802
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 53% 1% 30% 24% 38% 14% 21% 36% 6% 20% 20% 14% 11% 30% 7% 11% 17% 53% 14% 23% 41% 12% 5% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)51.550753
GSM780708Untreated after 4 days (C2_1)36.97741
GSM780709Untreated after 4 days (C3_1)45.489330
GSM780719Untreated after 4 days (C1_2)44.469324
GSM780720Untreated after 4 days (C2_2)47.261838
GSM780721Untreated after 4 days (C3_2)42.271814
GSM780710Trastuzumab treated after 4 days (T1_1)43.835621
GSM780711Trastuzumab treated after 4 days (T2_1)46.931736
GSM780712Trastuzumab treated after 4 days (T3_1)39.95656
GSM780722Trastuzumab treated after 4 days (T1_2)43.488720
GSM780723Trastuzumab treated after 4 days (T2_2)43.637420
GSM780724Trastuzumab treated after 4 days (T3_2)42.336414
GSM780713Pertuzumab treated after 4 days (P1_1)41.384211
GSM780714Pertuzumab treated after 4 days (P2_1)45.674930
GSM780715Pertuzumab treated after 4 days (P3_1)40.32247
GSM780725Pertuzumab treated after 4 days (P1_2)41.406911
GSM780726Pertuzumab treated after 4 days (P2_2)42.89717
GSM780727Pertuzumab treated after 4 days (P3_2)51.703253
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)42.273814
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)44.144323
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)48.037741
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)41.619712
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)39.61285